Skip to main content
REGNRegeneron Pharmaceuticals, Inc.Hold6.8·$957.76
HoldModerate Confidence
Investment thesis

Regeneron has beaten earnings estimates in all four of the last four quarters with an average surprise of 22%, trades at a forward price-to-earnings of 11.4x with 22% analyst upside, and maintains strong net margins of 30% — but faces declining earnings estimates, weak revenue growth, and near-term technical weakness from a death cross, creating a fundamentally sound but momentum-challenged setup.

Thesis pillars

  • Strong Margins And Financial Health→Stable
  • Perfect Earnings Beat Streak Quality→Stable
  • Attractive Valuation Versus Peers↓Deteriorating
  • +1 more pillar — see the Why tab for full reasoning

Pillars as of Jul 3, 2026, based on the 10-K filed Feb 4, 2026· older than 90 days

Full reasoning →

Open full analysis

Regeneron Pharmaceuticals, Inc. (REGN) Stock Analysis

HoldVALUE-TRAP 1/5GrowthModerate Confidence

Healthcare · Biotechnology

Hold if already holding. Not a fresh buy at $957.76, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away).

Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net product sales (31% of revenues) and Sanofi collaboration revenue from Dupixent (41% of revenues). The company has multiple approved products spanning ophthalmology,... Read more

$957.76-6.9% A.UpsideScore 6.8/10#5 of 240 Biotechnology
QualityF-score9 / 9FCF yield2.60%
IncomeYield0.39%Payout8.18%sustainable
Stop $890.72Analyst target $891.73(reached)A.R:R -0.5:1
Analyst consensus$990.81+3.5%27 analysts with price targets
$957.76price
$990.81mean
$812
$1175

Hold if already holding. Not a fresh buy at $957.76, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Score 6.8/10, moderate confidence.

Passes 7/8 gates (positive momentum, clean insider activity, no SEC red flags, news boost analyst 0.40, earnings proximity 71d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: speculative.

news + 30-day 8-K events · 5-min refresh

Recent developments

No fresh coverage since Oct 28, 2026

Recent Developments — Regeneron Pharmaceuticals, Inc.

Latest item Oct 28, 2026 · Generated 2026-11-18T11:27:30Z.

TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Thu, Jan 28, 202771d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (4/4)
High-quality business
Strong growth profile
Risks
Analyst target reached - limited upside remaining
Near 52-week high (3.4% away)

Key Metrics

P/E (TTM)21.1
P/E (Fwd)13.5
Mkt Cap$99.1B
EV/EBITDA15.9
Profit Mgn28.5%
ROE14.9%
Rev Growth36.3%
Beta0.10
Dividend0.39%
Analysts with ratings36

Quality Signals

Piotroski F9/9MoatWideCompounder✓

Options Flow

P/C0.69bullish
IV45%normal

Concentration Risks(10-K Item 1A)

  • MEDIUMProductEYLEA HD and EYLEA31%
    10-K Item 1A: 'our aggregate EYLEA HD and EYLEA net product sales in the United States represented 31%...of our total revenues'
  • MEDIUMcounterpartySanofi41%
    10-K Item 1A: 'Sanofi collaboration revenue (most of which is attributable to our share of profits from the commercialization of Dupixent) represented 41%...of our total revenues'

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

1 ceiling hit

GatesA.R:R -0.5=NEGATIVEMomentum 7.2>=5.5Insider activity: OKNo SEC red flagsNEWS BOOST ANALYST 0.40EARNINGS PROXIMITY 71d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARSuitability: Speculative
RSI
73 · Overbought
↑ 20D MA↑ 50D MA↑ 200D MAGOLDEN CROSSSupport $796.61Resistance $991.73

Price Targets

A.Upside-6.9%
A.R:R-0.5:1

Position Sizing

ConvictionNone
Suggested %0%
Max %0%
RegimeCautious

Risk Alerts

! Target reached (-6.9% upside)
! Negative risk/reward — downside exceeds upside

Earnings

B
B
B
B
4/4 beats
Next Earnings2027-01-28 (71d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is REGN stock a buy right now?

Hold if already holding. Not a fresh buy at $957.76, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Near 52-week high (3.4% away). Chart setup: No clear chart pattern; technical signals are mixed. Maintain position. Not compelling to add more. Analyst target $891.73 reached (−6.9%), stop $890.72 (−7.5%), A.R:R -0.5:1. Score 6.8/10, moderate confidence.

What is the REGN stock price target?

Analyst target $891.73 reached (−6.9% from $957.76); no take-profit level is published. Analyst target $891.73 reached (−6.9%), stop $890.72 (−7.5%), A.R:R -0.5:1. Stop-loss: $890.72.

What are the risks of investing in REGN?

Analyst target reached - limited upside remaining; Near 52-week high (3.4% away).

Is REGN overvalued or undervalued?

Regeneron Pharmaceuticals, Inc. trades at a P/E of 21.1 (forward 13.5). TrendMatrix value score: 5.8/10. Verdict: Hold.

What do analysts say about REGN?

36 analysts rate REGN, with a consensus score of 3.9/5. 27 analysts publish price targets averaging $991.

What does Regeneron Pharmaceuticals, Inc. do?Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net...

Regeneron Pharmaceuticals generated $14.3 billion in total revenues in 2025, driven by U.S. EYLEA HD and EYLEA net product sales (31% of revenues) and Sanofi collaboration revenue from Dupixent (41% of revenues). The company has multiple approved products spanning ophthalmology, immunology, oncology, and rare diseases, partnering with Sanofi and Bayer for select commercialization outside the US.

Related stocks: ARGX (argenx SE) · HALO (Halozyme Therapeutics, Inc.) · ASND (Ascendis Pharma A/S) · ONC (BeOne Medicines Ltd.) · BMRN (BioMarin Pharmaceutical Inc.)
Home › Stocks › REGN

Latest news

Latest News

MarketBeat49d ago
Yahoo Finance112d agoEarnings
Barron's203d agoEarnings
Investor's Business Daily203d agoProduct
Investor's Business Daily203d agoProduct
TradingKey203d ago
Investing.com203d ago
Seeking Alpha203d ago
Seeking Alpha203d ago
Quiver Quantitative203d agoEarnings
MarketBeat203d ago
Seeking Alpha21d agoEarnings
Yahoo Finance21d ago
PR Newswire84d agoLegal
MarketWatch84d ago
TMX Newsfile84d agoLegal
Morningstar84d agoLegal
Barchart.com84d ago
Simplywall.st119d ago
Quiver Quantitative119d ago
Loading more...